Oren Tomkins-Netzer1, Lazha Talat1, Asaf Bar1, Albert Lula2, Simon R J Taylor3, Lavnish Joshi1, Sue Lightman4. 1. Moorfields Eye Hospital, London, United Kingdom; Institute of Ophthalmology, University College of London, London, United Kingdom. 2. Institute of Ophthalmology, University College of London, London, United Kingdom. 3. Royal Surrey County Hospital, Egerton Road, Guildford, United Kingdom; Division of Immunology & Inflammation, Faculty of Medicine, Imperial College London, London, United Kingdom. 4. Moorfields Eye Hospital, London, United Kingdom; Institute of Ophthalmology, University College of London, London, United Kingdom. Electronic address: s.lightman@ucl.ac.uk.
Abstract
PURPOSE: To evaluate the long-term clinical and functional outcome, risks, and causes of vision loss and burden of disease among patients with uveitis. DESIGN: Cross-sectional study. PARTICIPANTS: The study included 1076 patients diagnosed with uveitis who attended the uveitis clinic at Moorfields Eye Hospital, London, United Kingdom, between 2011 and 2013. METHODS: Information was gathered from the notes of all patients who were examined in the clinic. MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA), causes of moderate vision loss (MVL; 20/50-20/120), and severe vision loss (SVL; ≤ 20/200). RESULTS: The study included 1799 eyes of 1076 patients with an average follow-up of 7.97 ± 0.17 years (median, 5.6 years; range, 1 month-54 years; 8159 patient-years; 14 226 eye-years). Average BCVA remained stable for patients with anterior uveitis (20/30 at baseline to 20/33 at 10 years), as well as for those with nonanterior uveitis (20/50 at baseline to 20/47 at 10 years). Vision loss was noted in 19.2% of eyes, with an incidence for MVL of 0.01 per eye-year or 0.02 per patient-year and for SVL of 0.01 per eye-year or 0.02 per patient-year. Patients were more at risk of vision loss if they had non-anterior uveitis disease, vitreous opacities, retinal detachment, cystoid macular edema (CME), macular scarring, macular hole, optic neuropathy, or macular ischemia. Chronic CME was the most common cause of MVL (3.55%), and macular scarring was the most common cause for irreversible SVL (4%). Among 525 patients (48.7%) who received oral prednisolone, 320 (61%) required a dose of more than 40 mg/day and 130 (24.8%) also required 1 or more second-line agents. Patients were reviewed on average 33.7 ± 0.7 times or 5.9 ± 0.46 times/year. CONCLUSIONS: Long-term functional outcome among uveitis patients is good, with BCVA remaining stable for more than 10 years of follow-up. In cases when vision loss occurs, it is related mainly to retinal changes. The burden on clinical services is similar regardless of the severity of disease or the risk of vision loss.
PURPOSE: To evaluate the long-term clinical and functional outcome, risks, and causes of vision loss and burden of disease among patients with uveitis. DESIGN: Cross-sectional study. PARTICIPANTS: The study included 1076 patients diagnosed with uveitis who attended the uveitis clinic at Moorfields Eye Hospital, London, United Kingdom, between 2011 and 2013. METHODS: Information was gathered from the notes of all patients who were examined in the clinic. MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA), causes of moderate vision loss (MVL; 20/50-20/120), and severe vision loss (SVL; ≤ 20/200). RESULTS: The study included 1799 eyes of 1076 patients with an average follow-up of 7.97 ± 0.17 years (median, 5.6 years; range, 1 month-54 years; 8159 patient-years; 14 226 eye-years). Average BCVA remained stable for patients with anterior uveitis (20/30 at baseline to 20/33 at 10 years), as well as for those with nonanterior uveitis (20/50 at baseline to 20/47 at 10 years). Vision loss was noted in 19.2% of eyes, with an incidence for MVL of 0.01 per eye-year or 0.02 per patient-year and for SVL of 0.01 per eye-year or 0.02 per patient-year. Patients were more at risk of vision loss if they had non-anterior uveitis disease, vitreous opacities, retinal detachment, cystoid macular edema (CME), macular scarring, macular hole, optic neuropathy, or macular ischemia. Chronic CME was the most common cause of MVL (3.55%), and macular scarring was the most common cause for irreversible SVL (4%). Among 525 patients (48.7%) who received oral prednisolone, 320 (61%) required a dose of more than 40 mg/day and 130 (24.8%) also required 1 or more second-line agents. Patients were reviewed on average 33.7 ± 0.7 times or 5.9 ± 0.46 times/year. CONCLUSIONS: Long-term functional outcome among uveitis patients is good, with BCVA remaining stable for more than 10 years of follow-up. In cases when vision loss occurs, it is related mainly to retinal changes. The burden on clinical services is similar regardless of the severity of disease or the risk of vision loss.
Authors: J Fernando Arevalo; Andres F Lasave; Turki Abdullah Al Ghamdi; Vishali Gupta; Igor Kozak; Hassan A Al Dhibi Journal: Graefes Arch Clin Exp Ophthalmol Date: 2019-06-08 Impact factor: 3.117
Authors: Oren Tomkins-Netzer; Susan Lightman; Lea Drye; John Kempen; Gary N Holland; Narsing A Rao; Richard J Stawell; Albert Vitale; Douglas A Jabs Journal: Ophthalmology Date: 2015-09-07 Impact factor: 12.079
Authors: Jessica G Shantha; Ian Crozier; Brent R Hayek; Beau B Bruce; Catherine Gargu; Jerry Brown; John Fankhauser; Steven Yeh Journal: Ophthalmology Date: 2016-11-30 Impact factor: 12.079
Authors: Natalia F Callaway; Marco A Gonzalez; Yoshihiro Yonekawa; Lisa J Faia; Efrem D Mandelcorn; Rahul N Khurana; Mohamed G A Saleh; Phoebe Lin; Lucia Sobrin; Thomas A Albini Journal: Retina Date: 2018-09 Impact factor: 4.256
Authors: Kongnara Papangkorn; Eri Prendergast; John W Higuchi; Balbir Brar; William I Higuchi Journal: J Ocul Pharmacol Ther Date: 2017-10-12 Impact factor: 2.671
Authors: John H Kempen; Michael M Altaweel; Janet T Holbrook; Elizabeth A Sugar; Jennifer E Thorne; Douglas A Jabs Journal: JAMA Date: 2017-05-16 Impact factor: 56.272